A randomized controlled clinical study comparing the effects of denosumab and teriparatide on lumbar spinal fusion and systemic bone loss after surgery

Start Date01 Apr 2025

Sponsor / Collaborator

Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital)

CTRI/2025/03/082184

/ Not yet recruitingNot Applicable

Effectiveness and Safety of Teriparatide in Fracture Healing: A Real- World Retrospective Study Based on Electronic Medical Records of Adult Osteoporotic Patients in India. - NIL

Start Date17 Mar 2025

Sponsor / Collaborator

Alkem Laboratories Ltd.

NCT06558188

/ RecruitingPhase 4IIT

Combined Anabolic Therapy Study

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Start Date03 Feb 2025

Sponsor / Collaborator

The General Hospital Corp.

100 Clinical Results associated with Teriparatide(Eli Lilly)

100 Translational Medicine associated with Teriparatide(Eli Lilly)

100 Patents (Medical) associated with Teriparatide(Eli Lilly)

128

Literatures (Medical) associated with Teriparatide(Eli Lilly)

01 Sep 2025·BIOMATERIALS

All-in-one design of titanium-based dental implant systems for enhanced soft and hard tissue integration

Article

Author: Liu, Xuanyong ; Feng, Jiayin ; Ye, Kuicai ; Qian, Wenhao ; Qiu, Jiajun ; Xing, Min ; Zhang, Haifeng

Enhancing the sealing between titanium abutment and surrounding soft tissue is crucial for preventing peri-implantitis. Meanwhile, exploring non-invasive antibacterial strategies as alternatives for traditional antibiotic therapy is central to improving the effect of peri-implantitis treatment. Furthermore, facilitating effective integration between titanium implant and osteoporotic bone is the cornerstone for ensuring long-term implant stability in patients with osteoporosis. In light of this, this work innovatively constructed multifunctional vertical graphene-based coatings on titanium implants and abutments using plasma-enhanced chemical vapor deposition technology. The results demonstrated that the vertical graphene coatings promoted soft tissue sealing and exhibited inherent antibacterial activities with the bacteriostasis rates of 65.60 % against Staphylococcus aureus (S. aureus) and 43.89 % against Escherichia coli (E. coli) in vitro which could prevent early infections. Moreover, vertical graphene coatings presented photothermal antibacterial effects with the antibacterial rates of 99.99 % and 95.83 % for S. aureus in vitro and in vivo, respectively, and 92.23 % for E. coli in vitro under near-infrared irradiation, which provided a non-invasive and highly effective treatment option for peri-implantitis. Furthermore, teriparatide acetate was loaded on vertical graphene coatings which enhanced osseointegration between titanium implants and osteoporotic bone. By comprehensively considering the critical functional requirements of dental implants and abutments, this work meticulously designed vertical graphene-based coatings on titanium dental implant systems for soft and hard tissue integration. This innovative design demonstrates immense application potential, especially for dental implant restoration in patients with osteoporosis.

12 Mar 2024·Journal of the Endocrine Society

Continuous Subcutaneous Delivery of rhPTH(1-84) and rhPTH(1-34) by Pump in Adults With Hypoparathyroidism

Article

Author: Cusano, Natalie E ; Mannstadt, Michael ; Bove-Fenderson, Erin ; Wong, Daniel ; Charoenngam, Nipith

Abstract:

Context:

Continuous subcutaneous infusion of recombinant parathyroid hormone (rhPTH) through a pump has been proposed as a therapeutic alternative for patients with chronic hypoparathyroidism who remain symptomatic or hypercalciuric on conventional treatment (calcium and active vitamin D) or daily injections of rhPTH(1-84) or rhPTH(1-34). However, the real-world evidence of the outcome of this novel therapy is limited.

Case Descriptions:

We report the clinical and biochemical outcomes of 12 adults with hypoparathyroidism (11 women, age 30-70 years, and 1 man, age 30 years) from 3 different clinical sites in the United States who were transitioned from conventional therapy to daily injections of rhPTH(1-84) or rhPTH(1-34) and then switched to continuous administration of rhPTH(1-84)/rhPTH(1-34) via pump therapy. In most patients, mean serum calcium concentrations increased while on PTH pump therapy compared with both conventional therapy (in 11 patients) and single/multiple daily rhPTH injections (in 8 patients). Despite this, 10 patients had lower median 24-hour urinary calcium levels while on PTH pump therapy compared with prior therapy (mean ± SD difference: −130 ± 222 mg/24 hours). All patients reported a qualitative decrease in hypocalcemic symptoms while receiving pump therapy. Three patients had pod failure at least once, and 1 patient developed an infusion site reaction.

Conclusion:

In this case series of 12 patients with chronic hypoparathyroidism treated with rhPTH(1-84)/rhPTH(1-34) administered via a pump, improvement in clinical and biochemical parameters were observed in the majority of the patients. Our observations indicate benefits of pump administration of rhPTH that warrant further investigation.

01 Aug 2022·Disease models & mechanisms

Pharmacological intervention of the FGF–PTH axis as a potential therapeutic for craniofacial ciliopathies

Article

Author: Brugmann, Samantha A. ; Kristeková, Daniela ; Chang, Ching-Fang ; Bonatto Paese, Christian Louis

ABSTRACT:

Ciliopathies represent a disease class characterized by a broad range of phenotypes including polycystic kidneys and skeletal anomalies. Ciliopathic skeletal phenotypes are among the most common and most difficult to treat due to a poor understanding of the pathological mechanisms leading to disease. Using an avian model (talpid2) for a human ciliopathy with both kidney and skeletal anomalies (orofaciodigital syndrome 14), we identified disruptions in the FGF23–PTH axis that resulted in reduced calcium uptake in the developing mandible and subsequent micrognathia. Although pharmacological intervention with the U.S. Food and Drug Administration (FDA)-approved pan-FGFR inhibitor AZD4547 alone rescued expression of the FGF target SPRY2, it did not significantly rescue micrognathia. In contrast, treatment with a cocktail of AZD4547 and teriparatide acetate, a PTH agonist and FDA-approved treatment for osteoporosis, resulted in molecular, cellular and phenotypic rescue of ciliopathic micrognathia in talpid2 mutants. Together, these data provide novel insight into pathological molecular mechanisms associated with ciliopathic skeletal phenotypes and a potential therapeutic strategy for a pleiotropic disease class with limited to no treatment options.

News (Medical) associated with Teriparatide(Eli Lilly)

15 May 2025

·www.prnewswire.com

Abzena Announces Establishment of Scientific Advisory Board to Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation. Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster." Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth. We look forward to their contributions and the positive impact that they will have on our organization." Founding members of Abzena's Scientific Advisory Board are: John Knight, Ph.D., is the founder of JKONSULT, a UK-based consulting firm, where he provides process chemistry and CMC consulting services for early-stage chemical development and transfer-to-plant projects, with a primary focus on material supplies for toxicological studies, Phase I, and Phase II clinical trials. Dr Knight has 38 years of pharmaceutical industry experience, with prior roles at GSK, Vernalis, and Evotec. Kamal Egodage, Ph.D., MBA, is the President of Lasanth® Consulting, where he provides consultation services for biologics that span from discovery through commercialization, including CMC development, regulatory strategy, interactions with health authorities, and corporate development strategy. Prior to establishing his consultancy in 2017, Dr. Egodage accumulated over 20 years of industry experience at Eli Lilly, Pharmacia, Monsanto, Symic Bio, and Novartis (Switzerland), where he was the Head of Strategy and Business Development for Biologics. Morris Rosenberg, D.Sc., is an independent consultant with over 25 years of experience in the development of therapeutic agents to treat a variety of human diseases. As a consultant, he provides advisory services to early research and clinical-stage companies on product development strategies for biologics, biosimilars, and ADC therapies. Prior to this, Dr Rosenberg played a key role in the development and commercialization of ADC-based therapies at Seattle Genetics and Immunomedics and participated in the development and launch of Trodelvy®, Adcetris®, Avonex®, Angiomax®, Xigris®, and Forteo®. Scott Rudge, Ph.D., co-founded RMC Pharmaceutical Solutions in 2004, which was acquired by Syner-G BioPharma Group in January 2023. He is a Principal Consultant with Syner-G, and leads its Commercial and Scientific Advisory Boards, and is a member of the Syner-G Board. He also currently serves as SVP of Product Development at Margaux Biologics, Head of CMC for Antidote Therapeutics and Optigo Biotherapeutics, is a Key Advisor to Jurata, and is an Adjunct Professor of Chemical Engineering at the University of Colorado. Dr Rudge has over 33 years of experience directing Process Engineering, Process Development, Product Development, and overall Pharmaceutical Operations, and has built and led several organizations in the biopharmaceutical industry. Steven Sandoval is the founder and serves as the CEO/ Operations Head of Pharmaceutical Technical Solutions, Inc. (PTSI). Providing technical oversight and client representative support to the Biotechnology, Gene Therapy, Viral Vector, Cell Therapy, T-CELL, CAR T, mRNA, 503a/ 503b Compounding, and Vaccine Pharmaceutical Industries since 2010. Prior to this, he held senior leadership roles at Pfenex Inc., Parsons (BMS), and Amgen. He has over 30 years of experience in biopharmaceutical manufacturing, operations, CMC tech transfer, engineering, facilities, and quality leadership services. Tatyana Touzova is the Chief Pharmaceutical Development & Manufacturing Officer at SERA Medicines, where she oversees CMC, regulatory, and nonclinical development from drug discovery through clinical stages. Prior to this, she held the position of Chief Operating Officer at AstralBio, AlmataBio, and ValenzaBio, where she directed CMC, manufacturing, and regulatory operations for multiple clinical-stage programs. She has over 35 years of experience in drug development, regulatory affairs, and commercial manufacturing of biologics and complex therapeutics and is recognized as an expert in CMC strategy, GMP compliance, and global regulatory submissions. About Abzena Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors. Learn more at abzena.com. SOURCE Abzena WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionPhase 2Executive Change

24 Oct 2024

·www.prnewswire.com

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug Administration (FDA) to develop standardized controls for T cell assays performed to assess the immunogenicity risk of generic drugs in support of ANDA applications as outlined in the relevant FDA guidance. The new contract will establish new "standards" that may be used to enhance specificity and sensitivity across industry assay methods. Generic peptide drugs (including generic versions of well-known brands like Ozempic and Wegovy) play a vital role in improving healthcare access by providing affordable and effective treatment options at a lower cost. FDA has been working to facilitate access to needed medicines at lower costs without sacrificing standards that result in high-quality, safe, and effective medications. See, for example, information provided by the FDA here. The new FDA-funded collaboration builds on research performed by EpiVax during two previous FDA contracts that evaluated the immunogenicity risk of generic drug impurities. Under the first contract, EpiVax demonstrated the value of in silico and in vitro methods for immunogenicity risk assessment of two well-known generic peptide drugs. Under the second contract, EpiVax developed the What-if Machine (WhIM), an algorithm designed to perform iterative modifications to the amino acid sequence of a synthetic peptide drug (in silico), generating a comprehensive list of impurities for that sequence, and prospectively identifying high and low risk impurities to allow for the de-risking of drug products. This information helps to 'frame' the risk for each generic drug and may assist drug developers and FDA reviewers to differentiate impurities that are potentially riskier from those that are lower risk. For the latest research program, EpiVax will identify and qualify standard peptide-sized positive and negative controls to support generic peptide drug ANDA applications for common generic drug peptides such as teriparatide, exenatide, liraglutide and tirzepatide. EpiVax's Peptide Abbreviated New Drug Application (PANDA ®) approach uses the same orthogonal methods utilized to identify and assess potentially immunogenic impurities for the FDA. The approach is described in a review titled "Immunogenicity Risk Assessment of Synthetic Peptide Drugs and Their Impurities." The details of one of the FDA-contracted programs were expanded upon in, "Assessing the Immunogenicity Risk of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods." EpiVax looks forward to executing this latest FDA-funded research in collaboration with CUBRC and continuing to improve access to safe and effective generic peptide drug products by leading in the development of new industry standards for generic peptide drug immunogenicity assessment. About EpiVax EpiVax is a leader in the industry of immunogenicity assessment and sequence optimization for peptide therapeutics, biologic therapeutics, and vaccines. EpiVax partners with a global roster of companies, agencies, and academics to accelerate immunogenicity risk assessment, immune modulation and rapid vaccine design. Visit for more information. About CUBRC CUBRC is an independent not-for-profit scientific corporation that executes Research, Development, Testing and Systems Integration programs in Medical Sciences, Chemical and Biological Defense, Data Science and Information Fusion, Command and Control, and Hypersonics. Visit for more information. FDA Funding Statement The FDA sponsors the project referenced in this press release. The content of the information does not necessarily reflect the position or the policy of the federal government, and no official endorsement should be inferred. The entire project (~$2M) will be financed with federal money. Press Contact Sarah Moniz Director, Business Development EpiVax [email protected] Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

10 Sep 2024

·www.prnewswire.com

Adcentrx Therapeutics Announces Formation of Scientific Advisory Board

Company appoints Mike Varney, Ph.D. and Kerry Blanchard, M.D., Ph.D. as founding SAB members SAN DIEGO and SHANGHAI, Sept. 10, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company focused on accelerating breakthroughs in developing protein conjugate therapeutics for cancer and other life-threatening diseases, today announces the formation of its Scientific Advisory Board (SAB) to support the advancement of its innovative Antibody-Drug Conjugate (ADC) technology platform and pipeline, including ADRX-0706, a Nectin-4 targeting ADC therapeutic currently being evaluated in a Phase 1a/b clinical trial. Continue Reading The inaugural SAB will work closely with Adcentrx's executive team to provide strategic guidance and expert insights to advance its mission of creating the best therapies to treat serious and life-threatening diseases. Formation of SAB with founding members Dr. Varney and Dr. Blanchard represents significant advancement for Adcentrx. Post this "The establishment of our SAB represents a significant advancement for Adcentrx as we progress our ADC portfolio," said Hui Li, Ph.D., President and CEO of Adcentrx. "We are privileged to welcome these exceptional scientific leaders to the Adcentrx team, and their combined expertise and guidance will be instrumental in shaping our future research and clinical development." The Founding Members of the Adcentrx SAB are: Mike Varney, Ph.D. Dr. Varney brings extensive experience in drug discovery and development, having served as Executive Vice President, Head of Genentech Research and Early Development, where he was responsible for all research activities. During his tenure at Genentech, he oversaw the discovery and development of multiple innovative therapies, including the approved cancer treatments Erivedge® and Cotellic®. Earlier in his career, Dr. Varney pioneered the use of protein-structure based drug design at Agouron Pharmaceuticals. This innovative approach led to the discovery and market approval of HIV protease inhibitor, Viracept®. After Agouron's acquisition by Warner Lambert and subsequently by Pfizer, he served as Vice President of Drug Discovery at Pfizer Global Research & Development, leading research initiatives across oncology, virology, diabetes, and ophthalmology at the La Jolla site. Dr. Varney holds a Ph.D. in Organic Synthesis from the California Institute of Technology and a B.S. in Chemistry from the University of California, Los Angeles, and was an American Cancer Society Postdoctoral Research Fellow at Columbia University. Kerry Blanchard, M.D., Ph.D. Dr. Blanchard has been a drug hunter and entrepreneur for more than four decades in the US and Asia. He is currently cofounder, Chairman, and CEO of Perpetual Medicines, a peptide therapeutics/computational AI platform company. Previously, he was the CEO of Everest Medicines, Chief Science Officer at Innovent Biologics, Senior Vice President of Lilly China Drug Development and External Innovation, and a senior executive at Eli Lilly and Company. He was a member of the board for Lilly China and Zymeworks Inc., and was the co-chairman of the Lilly Asia Ventures Investment Committee. Prior to joining Lilly in 2000, he was a tenured Professor of Medicine and Biochemistry & Molecular Biology at Louisiana State University Health Sciences Center in Shreveport, LA. Dr. Blanchard has brought four medicines to the market from his own research including Verzenio®, a CDK 4/6 inhibitor, and, his development teams in China have had more than 30 approved medicines in Asia including Trodelvy®, Trulicity®, Byetta®, Forteo®, and Tyvyt®. At Innovent and Everest, Dr. Blanchard successfully raised over $2 billion to support and expand their pipelines. His track record in accelerating clinical development and navigating regulatory landscapes will significantly enhance Adcentrx's strategic initiatives and global expansion. Dr. Blanchard received his M.D. and Ph.D. in Biochemistry from Indiana University and completed his residency and fellowships at Brigham and Women's Hospital, Dana Farber Cancer Institute, and Harvard Medical School. About Adcentrx Therapeutics Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. Adcentrx has pioneered the development of i-Conjugation™, an ADC technology platform addressing key components of protein conjugate design to solve challenges typically seen in ADCs. In addition to ADRX-0706, Adcentrx is developing a robust pipeline of ADCs with first-in-class potential. For more information about Adcentrx and its innovative ADC technologies, please visit . Contact Information: Investor Relations [email protected] SOURCE Adcentrx Therapeutics

Executive ChangeAcquisitionADC

100 Deals associated with Teriparatide(Eli Lilly)

External Link

KEGG	Wiki	ATC	Drug Bank
D06078	Teriparatide(Eli Lilly)	H05AA02	DB06285

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glucocorticoid-induced osteoporosis	Australia	Eli Lilly Australia Pty Ltd.	22 May 2003
Osteoporosis, Postmenopausal	Australia	Eli Lilly Australia Pty Ltd.	22 May 2003
Primary osteoporosis	Australia	Eli Lilly Australia Pty Ltd.	22 May 2003
Osteoporosis	United States	Eli Lilly & Co.	26 Nov 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Femoral Fractures	Phase 3	Canada	Eli Lilly & Co.	01 Jul 2013
Femoral Neck Fractures	Phase 3	United States	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Belgium	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Croatia	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	France	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Germany	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Greece	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Hungary	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	India	Eli Lilly & Co.	01 Jan 2012
Femoral Neck Fractures	Phase 3	Netherlands	Eli Lilly & Co.	01 Jan 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


FDA_CDER Manual	Not Applicable	Osteoporosis, Postmenopausal	1,637	Teriparatide	ofqmmwxwwm(chstgrhach) = zckizqiqfw jleurdpytb (cszoxgxahz ) View more	Positive	04 Jun 2024
				Placebo	ofqmmwxwwm(chstgrhach) = npwdnnkuec jleurdpytb (cszoxgxahz ) View more
FDA_CDER Manual	Not Applicable	Hypogonadal osteoporosis \| Primary osteoporosis	-	Teriparatide	lqjgzdbzov(wgdvevimvf) = juuvlcgbah gigjpvtsrb (inrmtckrsp ) View more	Positive	04 Jun 2024
				Placebo	lqjgzdbzov(wgdvevimvf) = spjbtcpknh gigjpvtsrb (inrmtckrsp ) View more
FDA_CDER Manual	Not Applicable	Glucocorticoid-induced osteoporosis	428	Teriparatide	edqaurfynx(qhzldalwoo) = yiwobbrgbf fzljzlqeph (ncnxqxvjee ) View more	Positive	04 Jun 2024
				prednisone or equivalent	-
SAT235 (ENDO2023)	Phase 1	-	29	RT-102/20 µg	gjpvqdsqsy(mvsyupjcqs) = 3- to 4-fold higher compared to the SC injection group annienqbwu (acelfrqctq ) View more	Positive	05 Oct 2023
				RT-102/80 µg
NCT04026256 (CTgov)	Phase 4	Osteoporosis, Postmenopausal	37	Teriparatide (Teriparatide Only)	rhjeyvegyd(eehykeycfd) = pvaspkuplc xjozaftwxu (uqaxfpabql, 0.06) View more	-	02 Aug 2023
				Denosumab (Denosumab Only)	rhjeyvegyd(eehykeycfd) = ovjipucdbg xjozaftwxu (uqaxfpabql, 0.01) View more
PSAT182 (ENDO2022)	Not Applicable	Alkaptonuria \| Osteoporosis	-	Alendronate 70mg PO weekly	dithvbysvd(rabslttfme) = ukybpbiumq lxhxrgvcsh (krqukkxoam ) View more	Positive	01 Nov 2022
EULAR2022	Not Applicable	-	25	Teriparatide + Denosumab	qfolhsfsgq(ygwcyurfyl) = ornzruhfed dkfanlbdjp (yopbpsipkf, 3.6%) View more	-	01 Jun 2022
				Denosumab alone	qfolhsfsgq(ygwcyurfyl) = dfejktnbtz dkfanlbdjp (yopbpsipkf, 3.6%) View more
OUR EXPERIENCE AND ANALYSIS OF QUALITY OF LIFE AND CHANGES IN BMD (WCO_IOF_ESCEO2022)	Not Applicable	-	15	Teriparatide (group 1)	fndudgfjra(sjexizunal) = stzlfumuiq uozofrxlkz (epdxwheyvc ) View more	Positive	24 Mar 2022
				Teriparatide (group 2)	fndudgfjra(sjexizunal) = ucrtkmxwxx uozofrxlkz (epdxwheyvc ) View more
WCO_IOF_ESCEO2021	Not Applicable	Osteoporosis	12	Teriparatide	cglcxqpqmv(wizlfscogf) = eglragrteq qbqepbxfwq (uontcnzixq )	Positive	26 Aug 2021
NCT02176382 (DATA-HD, CTgov)	Phase 4	Osteoporosis, Postmenopausal	76	Zoledronic acid+teriparatide+denosumab (Standard Dose Teriparatide)	hfsnlntjpo(rsfbbngmds) = ihrnazlfsb dwvmujiyen (ddgkfwxnqj, 4.66) View more	-	22 Jan 2021
				Zoledronic acid+teriparatide+denosumab (High Dose Teriparatide)	hfsnlntjpo(rsfbbngmds) = vjpbruawdh dwvmujiyen (ddgkfwxnqj, 5.54) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis